摘要
目的 :探讨多发性骨髓瘤 (MM)患者血清白细胞介素 6(IL-6)及血清可溶性白细胞介素 6受体 (s IL-6R)水平及临床意义。方法 :联合检测 2 4例 MM患者化疗前后血清 IL-6及 s IL-6R水平。结果 :初诊时血清 IL-6及 s IL-6R较正常对照组显著增高 (P<0 .0 1 )。 MM患者 s IL-6R水平与疗效及病情活动有关。有效组用药后 s IL-6R明显下降 ,低于无效组 (P<0 .0 1 ) ,无效组用药后变化不明显 (P>0 .0 5 )。动态观察发现 s IL-6R水平与骨髓浆细胞比例的变化相一致。结论 :初诊MM患者血清 IL-6及 s IL-6R较正常对照组显著增高。血清 s IL-6R可作为估计 MM疗效。
Objective:To study the clinical significance of IL 6 and sIL 6R in patients with multiple myeloma (MM).Methods:Serum levels of IL 6 and sIL 6R in patients with MM before and after chemotherapy were measured.Results:Serum levels of IL 6 and sIL 6R in initial patients with MM were significantly higher than that in normal controls ( P <0 01). The levels of IL 6 and sIL 6R were related to response for chemotherapy. The serum levels of sIL 6R in responder group was significantly lower than that in non responder group after chemotherapy ( P <0 01). The serum levels of non responder group changed in significantly after chemotherapy ( P >0 05). Conclusion:Serum levels of IL 6 and sIL 6R were increased signicantly in patients with MM.Thus, serum level of sIL 6R is a indicator to evaluate the response of MM to chemotherapy and to assess the prognosis of a patient with MM.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2002年第3期289-290,共2页
Journal of Jilin University：Medicine Edition
